Dexamethasone-palmitate-DXP-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEDexamethasonepalmitateCat.No.:HY-128922CASNo.:14899-36-6Synonyms:DXP分⼦式:C₃₈H₅₉FO₆分⼦量:630.87作⽤靶点:Others作⽤通路:Others储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:50mg/mL(79.26mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM1.5851mL7.9256mL15.8511mL5mM0.3170mL1.5851mL3.1702mL10mM0.1585mL0.7926mL1.5851mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥2.08mg/mL(3.30mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(3.30mM);Suspendedsolution;Needultrasonic3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(3.30mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Dexamethasonepalmitate(DXP)Dexamethasone(HY-14648)的前体药物。Dexamethasonepalmitate可⽤于炎症的研究。体外研究Dexamethasonepalmitate(100μg/mL;48h)affectscytokinesconcentrationofRAW264.7cells[1].CellViabilityAssay[1]CellLine:RAW264.7cellsConcentration:100μg/mLIncubationTime:48hoursResult:Showedvitroanti-inflammatoryeffectsanddecreasedLPS-inducedMCP-1andTNF-αconcentrationinRAW264.7cells.体内研究Dexamethasonepalmitate(1280μg;IVTinjectiononce)showsdifferentdistributioninoculartissueatdifferenttimes[2].Dexamethasonepalmitate(280-1280μg;IVTinjectiononce)affectsVEGF-inducedvascularhyperpermeability[2].AnimalModel:NewZealandWhiterabbits[2]Dosage:1280μgAdministration:IVTinjection;1280μgonceResult:Mostlydistributedinvitreousandstillexistedtill9months.Theleastdistributedinaqueoushumorandalmostdisappearedtill6months.AnimalModel:NewZealandWhiterabbitswithVEGFinjection[2]Dosage:280,560and1280μgAdministration:IVTinjection;280-1280μgonceResult:After9monthsadministrationVEGF-inducedvascularpermeabilitywascontrolledataconcentrationof1280μg,besides280and560μgalsoreducedVEGF-inducedvascular2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEhyperpermeabilityafteradministrationfor4months.REFERENCES[1].LorscheiderM,etal.Dexamethasonepalmitatenanoparticles:Anefficienttreatmentforrheumatoidarthritis.JControlRelease.2019Feb28;296:179-189.[2].DaullP,etal.Apreliminaryevaluationofdexamethasonepalmitateemulsion:anovelintravitrealsustaineddeliveryofcorticosteroidfortreatmentofmacularedema.JOculPharmacolTher.2013Mar;29(2):258-69.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformed